February 7, 2014
The landscape of hepatitis C (HCV) management has undergone a near-fundamental transformation over the past couple of years. As new treatment options puff up like popcorn kernels on a hot stove and our understanding of the virus deepens, it's important to revisit what's changed -- and what further changes 2014 may hold in store.
Late in 2013, Andrea Cox, M.D., Ph.D., an associate professor of medicine at Johns Hopkins University School of Medicine, presented an update on HCV coinfection for an audience of HIV care providers. Read on for a summary of key points from her talk, including selected slides (which have been reposted with her permission).
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|Inflammation Persists Despite Very Early HIV Treatment|
|Markers of Immune Exhaustion Predict Post-Treatment Control in HIV Patients|
|Ben Young: CROI 2015 Data Bolster the Call for Initiative to End HIV/AIDS Epidemic|
|New PrEP Results Exceed HIV Researchers' High Expectations|
|Coverage of CROI 2015: The 22nd Conference on Retroviruses and Opportunistic Infections|
|Women and PrEP: The Bridging Role of Local Health Departments|